Benzinga’s Top Ratings Upgrades, Downgrades For January 4, 2023
Upgrades UBS upgraded the previous rating for Trane Technologies PLC (NYSE:TT) from Neutral to Buy. For the third…
SVB Leerink Maintains Outperform on Deciphera Pharmaceuticals, Raises Price Target to $28
SVB Leerink analyst Andrew Berens maintains Deciphera Pharmaceuticals (NASDAQ:DCPH) with a Outperform and raises the price target from $25 to $28.
Guggenheim Upgrades Deciphera Pharmaceuticals to Buy, Announces $22 Price Target
Guggenheim analyst Michael Schmidt upgrades Deciphera Pharmaceuticals (NASDAQ:DCPH) from Neutral to Buy and announces $22 price target.
Analyst Bullish On Theseus Pharma’s Platform For Gastric Cancer Therapies
Needham has initiated coverage on Theseus Pharmaceuticals Inc (NASDAQ:THRX) with a Buy rating and a price target of $22. Theseus’ discovery platform…
Deciphera Pharmaceuticals Q3 EPS $(0.55) Beats $(0.58) Estimate, Sales $35.97M Beat $33.15M Estimate
Deciphera Pharmaceuticals (NASDAQ:DCPH) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $(0.58) by 5.17 percent. This is a 59.85 percent increase over losses of $(1.37) per
Earnings Scheduled For November 3, 2022
Companies Reporting Before The Bell
• Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.
Earnings Outlook For Deciphera Pharmaceuticals
Deciphera Pharmaceuticals (NASDAQ:DCPH) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement.
Analysts estimate that Deciphera Pharmaceuticals will report an earnings per share (EPS) of $-0.58.
Deciphera Earns Price Target Bump With Encouraging ESMO Presentation
Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) announced positive initial data from the single agent dose escalation portion of the Phase 1 study of…
Bristol-Myers Squibb To $87? Here Are 5 Other Price Target Changes For Monday
Atlantic Equities raised the price target on Bristol-Myers Squibb Company (NYSE: BMY) from $83 to $87. Atlantic Equities analyst Steve Chesney maintained an Overweight rating on the stock. Bristol-Myers Squibb shares rose 6.3% to $74.60 in pre-market trading.
SVB Leerink Maintains Outperform on Deciphera Pharmaceuticals, Raises Price Target to $25
SVB Leerink analyst Andrew Berens maintains Deciphera Pharmaceuticals (NASDAQ:DCPH) with a Outperform and raises the price target from $21 to $25.